The benefit-to-risk ratio of common treatments in PCOS: Effect of oral contraceptives versus metformin on atherogenic markers

Hormones

Volumn 13, Issue 4, 2014, Pages 488-497

  Christakou, Charikleia ^a   Kollias, Anastasios ^a   Piperi, Christina ^b   Katsikis, Ilias ^c   Panidis, Dimitrios ^c   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Atherogenic markers; Metformin; Oral contraceptives; Polycystic ovary syndrome

Indexed keywords

ADVANCED GLYCATION END PRODUCT; C REACTIVE PROTEIN; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; METFORMIN; ANDROSTANE DERIVATIVE; BIOLOGICAL MARKER; CYPROTERONE ACETATE; ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; ORAL CONTRACEPTIVE USE; OVARY POLYCYSTIC DISEASE; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; METABOLISM; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANDROSTENES; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; CYPROTERONE ACETATE; ETHINYL ESTRADIOL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; METFORMIN; POLYCYSTIC OVARY SYNDROME; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84916237551     PISSN: 11093099     EISSN: 25208721     Source Type: Journal    
DOI: 10.14310/horm.2002.1553     Document Type: Article

References (31)

1. Diamanti-Kandarakis E, Dunaif A, 2012 Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33: 981-1030.
2. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al, 2008 Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 69: 634-641.
3. Vlassara H, 2005 Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 1043: 452-460.
4. Diamanti-Kandarakis E, Piperi C, Patsouris E, et al, 2007 Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 127: 581-589.
5. Baillargeon JP, McClish DK, Essah PA, Nestler JE, 2005 Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a metaanalysis. J Clin Endocrinol Metab 90: 3863-3870.
6. Merz CN, Johnson BD, Berga S, Braunstein G, Reis SE, Bittner V, WISE Study Group, 2006 Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Fertil Steril 85: 1425-1431.
7. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al, 2006 Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21: 1426-1431.
8. Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al, 2007 Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 56: 129-134.
9. Zawadski JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE (eds) Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), Blackwell Scientific Inc, Boston; p, 377.
10. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G, 2005 Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62: 37-43.
11. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS, 2003 Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 88: 148-156.
12. Nader S, Diamanti-Kandarakis E, 2007 Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 22: 317-322.
13. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti- Kandarakis E, Creatsas G, 2006 Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome Fertil Steril 85: 420-427.
14. Teede HJ, Meyer C, Hutchison SK, Zoungas S, McGrath BP, Moran LJ, 2010 Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. Fertil Steril 93: 184-191.
15. González F, 2012 Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77: 300-305.
16. Christakou C, Diamanti-Kandarakis E, 2013 Structural, biochemical and non-traditional cardiovascular risk markers in PCOS. Curr Pharm Des 19: 5764-5774.
17. Jabbour HN, Sales KJ, Catalano RD, Norman JE, 2009 Inflammatory pathways in female reproductive health and disease. Reproduction 138: 903-919.
18. Corrado E, Rizzo M, Coppola G, et al, 2010 An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 17: 1-11.
19. Rusa R, Alkayed N, Crain B, et al, 1999 17beta-estradiol reduces stroke injury in estrogen-deficient female animals. Stroke 30: 1665-1670.
20. Mukherjee TK, Reynolds PR, Hoidal JR, 2005 Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta 1745: 300-309.
21. Mukhopadhyay S, Mukherjee TK, 2005 Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective. Biochim Biophys Acta 1745: 145-155.
22. Kislinger T, Tanji N, Wendt T, et al, 2001 Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 21: 905-910.
23. Schmidt AM, Yan SD, Wautier JL, Stern D, 1999 Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 84: 489-497.
24. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B, Jialal I, 2003 Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J Am Coll Cardiol 41: 1358-1363.
25. Palacios S, Foidart JM, Genazzani A, 2006 Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 55: 297-307.
26. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR, 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557-1565.
27. Packard R, Libby P, 2008 Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction. Clin Chem 54: 24-38.
28. Beisswenger PJ, Ruggiero-Lopez D, 2003 Metformin inhibition of glycation processes. Diabetes Metab 29(4 Pt 2): 695-703.
29. Tanaka Y, Iwamoto H, Onuma T, Kawamori R, 1997 Inhibitory effect of metformin on formation of advanced glycation end products. Curr Ther Res 58: 693-697.
30. Tanaka Y, Uchino H, Shimizu T, et al, 1999 Effect of metformin on advanced glycation end product formation and peripheral nerve function in streptozotocin-induced diabetic rats. Eur J Pharmacol 376: 17-22.
31. Bhattacharya SM, Jha A, 2012 Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril 98: 1053-1059.